甘精胰岛素联合瑞格列奈在治疗2型糖尿病患者中的临床效果及对血糖水平的影响  

Clinical Effect of Insulin Glargine Combined with Repaglinide in the Treatment of Type 2 Diabetes Patients and Its Influence on Blood Glucose Level

作　　者：雍力 YONG Li(Department of Internal Medicine,Nanjing County Hospital,Zhangzhou 363601,China)

机构地区：[1]福建省漳州市南靖县医院内科,漳州363601

出　　处：《中国医药指南》2024年第19期59-62,共4页Guide of China Medicine

摘　　要：目的 观察甘精胰岛素联合瑞格列奈治疗2型糖尿病(T2DM)的临床疗效以及对血糖水平的影响。方法 本研究共纳入样本病例88例,均来自南靖县医院2023年1—12月收治的T2DM患者,经随机数字表法以1∶1分为观察组(44例)和对照组(44例),对照组接受瑞格列奈口服治疗,观察组患者在对照组基础上加用甘精胰岛素注射治疗。对比两组患者连续治疗3个月后的血糖指标、血糖波动幅度、胰岛素相关指标、不良反应发生情况。结果 治疗后,观察组空腹血糖(5.58±1.16)mmol/L、餐后2 h血糖为(9.19±0.89)mmol/L、糖化血红蛋白(6.32±0.74)%,分别低于对照组的(7.22±1.07)mmol/L、(12.03±1.07)mmol/L、(8.54±1.11)%(均P <0.05);治疗后,观察组平均血糖波动幅度、最大血糖波动幅度、日间血糖平均绝对值变化均低于对照组(均P <0.05);治疗后,观察组的空腹胰岛素、餐后2 h胰岛素、胰岛β细胞功能指数(HOMA-β)均高于对照组(均P <0.05);两组不良反应发生率均较低,差异无统计学意义(P> 0.05)。结论 为T2DM患者应用甘精胰岛素+瑞格列奈治疗的效果显著优于单纯瑞格列奈治疗,患者血糖水平得以明显控制,波动幅度较小,胰岛素相关指标改善,治疗期间不良反应可控。Objective To observe the clinical efficacy of insulin glargine combined with repaglinide in the treatment of type 2 diabetes mellitus(T2DM) and its influence on blood glucose level.Methods A total of 88 sample cases were included in this study,all of whom were type 2 diabetes patients admitted to Nanjing County Hospital from January to December 2023.They were randomly divided into the observation group(n=44) and the control group(n=44) at a ratio of 1:1.The control group received oral treatment of repaglinide,and the patients in the observation group received insulin glargine injection on the basis of the control group.Compare the blood glucose indicators,blood glucose fluctuation amplitude,insulin related indicators,and incidence of adverse reactions between two groups of patients after continuous treatment for 3 months.Results After treatment,the fasting blood glucose of the observation group was(5.58±1.16) mmol/L,the blood glucose 2 hours after meal was(9.19±0.89) mmol/L,and the glycated hemoglobin was(6.32±0.74)%,which were lower than those of the control group(7.22±1.07) mmol/L,(12.03±1.07) mmol/L,(8.54±1.11)% respectively(P<0.05);After treatment,the average blood glucose fluctuation amplitude,maximum blood glucose fluctuation amplitude,and daily blood glucose average absolute value change in the observation group were all lower than those in the control group(P<0.05);After treatment,the fasting insulin,2-hour postprandial insulin,and pancreatic islets in the observation group were measured β Cellular Function Index(HOMA)-β) All were higher than the control group(P<0.05);The incidence of adverse reactions in both groups was relatively low,and the difference was not statistically significant(P>0.05).Conclusions Applying glargine insulin + repaglinide therapy for T2DM patients,the clinical effect is significantly superior to pure repaglinide therapy.The blood sugar levels of patients are clearly controlled,with reduced fluctuation ranges,improved insulin-related indicators,and controllable adverse reac

关 键 词：2型糖尿病 甘精胰岛素 瑞格列奈 临床效果 血糖水平 

分 类 号：R587.1[医药卫生—内分泌]